stockrowArrowhead Pharmaceuticals, Inc.
ARWR Healthcare Biotechnology
Arrowhead Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $829.4 million, up 23,258.2% from fiscal 2024.
- Revenue
- +171.0%
- EPS
- −7.94%
- Free cash flow
- −15.4%
- Total debt
- +259.5%
Quarter to June 2026, against a year earlier
Follow ARWR
Alert me
Arrowhead Pharmaceuticals, Inc. (ARWR) Current ratio
Arrowhead Pharmaceuticals, Inc.'s current ratio at the end of the quarter to 30 June 2026 was 5.9×, up 1.0× from fiscal 2025 (4.9×). Over the past ten years it has ranged from 2.6× (fiscal 2021) to 7.9× (fiscal 2020); the current reading is higher than 64% of that period. That is above the Biotechnology industry median of 4.9× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 4.9× | (27.86%) |
| FY2024 | 6.7× | 70.70% |
| FY2023 | 3.9× | 35.29% |
| FY2022 | 2.9× | 11.22% |
| FY2021 | 2.6× | (66.88%) |
| FY2020 | 7.9× | 190.00% |
| FY2019 | 2.7× | (57.11%) |
| FY2018 | 6.4× | 75.44% |
| FY2017 | 3.6× | 2.88% |
| FY2016 | 3.5× | (45.45%) |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 5.9× | (5.34%) |
| Mar 2026 | 6.2× | 84.36% |
| Dec 2025 | 3.4× | (30.49%) |
| Sep 2025 | 4.9× | (0.10%) |
| 42 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| SYRE Spyre Therapeutics, Inc. compare | 27.4× |
| PTGX Protagonist Therapeutics, Inc. compare | 21.7× |
| KRYS Krystal Biotech, Inc. compare | 7.9× |
| CAI Caris Life Sciences,�Inc. compare | 6.7× |
| ARWR Arrowhead Pharmaceuticals, Inc. | 5.9× |
| CYTK Cytokinetics, Incorporated compare | 3.4× |
| MDGL Madrigal Pharmaceuticals, Inc. compare | 3.1× |
| CORT Corcept Therapeutics Incorporated compare | 3.0× |
| TWST Twist Bioscience Corporation compare | 2.7× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on ARWR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement